A Look At Avient’s (AVNT) Valuation After Keybanc Downgrade Shifts Rating To Sector Weight

Keybanc analyst Aleksey Yefremov recently shifted his rating on Avient (AVNT) from Overweight to Sector Weight, a change that puts fresh attention on how the stock compares with its peers.

See our latest analysis for Avient.

Avient shares recently pulled back, with a 1 day share price return of a 3.65% decline and a 30 day share price return of a 4.15% decline. However, the 1 year total shareholder return of 21.30% and the year to date share price return of 10.60% suggest momentum has generally been building ahead of the upcoming first quarter 2026 earnings release, against a backdrop of mixed analyst views.

If this rating change has you rethinking your watchlist, it can help to scan other materials names and compare their setups using the 20 top founder-led companies

With Avient trading at $35.07 against an average analyst price target of $48.57 and an indicated intrinsic discount of roughly 33%, the question is whether this represents genuine value or if markets already anticipate potential future growth.

Most Popular Narrative: 27.8% Undervalued

Compared with Avient's last close at $35.07, the most followed narrative places fair value nearer $48.57, framing the current pullback as a potential discount to its long term earnings story.

Ongoing footprint optimization, Lean Six Sigma initiatives, and discretionary spending controls are structurally lowering operating costs and improving productivity, leading to sustained improvements in EBITDA margins and higher free cash flow generation. Strategic deleveraging of the balance sheet enables increased capacity for reinvestment in growth vectors like healthcare and sustainability, reducing financial risk and supporting stronger EPS growth and enterprise value over the long term.

Read the complete narrative.

Want to see what sits underneath that fair value estimate? The narrative leans heavily on faster earnings growth, firmer margins and a punchy future earnings multiple. Curious which assumptions really move the model.

Result: Fair Value of $48.57 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, that fair value story can easily wobble if raw material costs stay elevated or if weak demand in key end markets keeps revenue and margins under pressure.

Find out about the key risks to this Avient narrative.

Another Way To Look At The Valuation

While the narrative and SWS DCF work suggest Avient is trading below an estimate of fair value at $52.70 per share, the current P/E of 39.3x tells a different story. That level is well above the US Chemicals industry at 29.2x, the peer average at 25.1x, and the fair ratio of 26.5x.

For you, that gap means the market is already putting a rich price on today's earnings, which can limit room for error if the long term story does not play out as expected. The tension between a discounted cash flow signal and a premium earnings multiple is exactly where valuation risk, or opportunity, often sits. Which side do you think deserves more weight?

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Mixed signals on value and risk so far. If you want to cut through the noise quickly and shape your own view, start by weighing the 3 key rewards and 4 important warning signs.

Looking for more investment ideas?

If Avient is on your radar, do not stop there. Widening your search now can reveal other opportunities that fit your style before the crowd catches on.

• Target potential mispricings by scanning companies that look attractively valued on quality and fundamentals using the 58 high quality undervalued stocks.
• Strengthen your income game by checking out companies aiming for yields above 5% and robust payouts with the 13 dividend fortresses.
• Reduce stress in your portfolio by hunting for financially resilient names screened through the 67 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com